{
    "organizations": [],
    "uuid": "b81d671fdb9573e7cb48d44c5b9ec42b17b7cf53",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sanofi-fda-to-conduct-priority-rev/brief-sanofi-fda-to-conduct-priority-review-of-cemiplimab-as-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-idUSASO00040Q",
    "ord_in_thread": 0,
    "title": "BRIEF-Sanofi: FDA To Conduct Priority Review Of Cemiplimab As Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - SANOFI SA:\n* REG-SANOFI: FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-30T13:05:00.000+03:00",
    "crawled": "2018-05-01T20:26:09.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "sanofi",
        "sa",
        "fda",
        "conduct",
        "priority",
        "review",
        "cemiplimab",
        "potential",
        "treatment",
        "advanced",
        "cutaneous",
        "squamous",
        "cell",
        "carcinoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}